severe hemophilia A
severe hemophilia A
Explore linked clinical trials. Standard reference: MONDO:001571910 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia A, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder, severe hemophilia A | Active, not recruiting | Phase 3 | 2026-10-01 | NCT04431726 | |
| Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia A, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder, severe hemophilia A | Active, not recruiting | Phase 3 | 2026-09-08 | NCT07663903 | |
| Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment. | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia A, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder, severe hemophilia A | Active, not recruiting | Phase 3 | 2026-09-04 | NCT07684898 | |
| A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia A, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder, severe hemophilia A | Active, not recruiting | Phase 4 | 2026-07-27 | NCT05181618 | |
| A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A. | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia A, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder, severe hemophilia A | Recruiting | Phase 1 | 2026-06-03 | NCT06703606 | |
| Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia A, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder, severe hemophilia A | Recruiting | Phase 4 | 2026-05-12 | NCT05935358 | |
| To Evaluate the Safety and Efficacy of GS1191-0445 Injection in the Treatment of Severe Hemophilia A | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia A, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder, severe hemophilia A | Active, not recruiting | Phase 1 / Phase 2 | 2026-05-06 | NCT07548411 | |
| Palliative Care Needs of Children With Rare Diseases and Their Families | Abnormalities, Multiple, Bone Diseases, Developmental, CHARGE syndrome, Cardiovascular Abnormalities, Cockayne syndrome, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Craniofacial Abnormalities, DNA repair disease, Deaf-Blind Disorders, Deafness, Digestive System Diseases, Disease Attributes, Dwarfism, Ear Diseases, Eye Diseases, Hereditary, FOXG1 disorder, Hemic and Lymphatic Diseases, Hernia, Hernia, Diaphragmatic, Internal Hernia, KBG syndrome, Musculoskeletal Abnormalities, Neurobehavioral Manifestations, Neurologic Manifestations, Noonan syndrome, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Postoperative Complications, Rare Diseases, Sensation Disorders, Signs and Symptoms, Skin and Connective Tissue Diseases, anxiety disorder, blindness (disorder), blood coagulation disease, bone disorder, cardiovascular disorder, chromosomal disorder, coagulation protein disease, coloboma, congenital diaphragmatic hernia, congenital heart disease, congenital microcephaly - severe encephalopathy - progressive cerebral atrophy syndrome, connective tissue disorder, depressive disorder, digestive system disorder, eye disorder, factor VII deficiency, hearing disorder, hearing loss disorder, heart disorder, hematologic disorder, hemophilia A, hemorrhagic disease, hereditary disease, infantile epileptic-dyskinetic encephalopathy, inherited blood coagulation disorder, inherited neurodegenerative disorder, intellectual disability, intestinal disorder, malabsorption syndrome, metabolic disease, musculoskeletal system disorder, nervous system disorder, neurodegeneration with brain iron accumulation 5, neurodegenerative disease, otorhinolaryngologic disease, psychiatric disorder, severe hemophilia A, short bowel syndrome, trisomy 13, vision disorder | Enrolling by invitation | Not applicable | 2026-01-28 | NCT06938542 | |
| Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia A, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder, severe hemophilia A | Not yet recruiting | Phase 3 | 2024-06-20 | NCT06136507 | |
| Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia A, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder, severe hemophilia A | Recruiting | Not stated | 2023-07-10 | NCT05802836 |